Aptose Biosciences ended its blood cancer collaboration tied to CG-806 after its pending takeover by Hanmi Pharmaceutical constrained further development options. The deal unwound after Aptose exercised an option return mechanism, reverting rights and materials/data back to CrystalGenomics. The company said the transaction completion has been delayed by Korean regulatory processes, leaving Aptose unable to pursue additional work on the candidate despite prior studies aimed at improving absorption and tolerability. Aptose cited financial constraints, including cash runway considerations, as it redirected priorities toward tuspetinib. For dealmaking and pipeline management, the episode illustrates how M&A timelines can abruptly reshape development portfolios, prompting license reversions and narrowing near-term execution options.